Shows neuroimmune and ovarian alterations in female rats after low-dose tributyltin exposure, indicating environmental disruptors' risks.
Tributyltin (TBT) is a persistent environmental endocrine disruptor with documented neurotoxic and reproductive effects, yet its impact on coordinated brain–ovary immune–endocrine regulation remains unclear. This study investigated whether subchronic, low-dose TBT exposure is associated with parallel alterations in these tissues. Female Wistar rats were exposed to TBT (50, 100, 300 ng/kg/day) with or without fucoxanthin (Fx, 20 mg/kg/day) for four weeks. Brain and ovarian tissues were assessed via histopathology, immunohistochemistry (NF‑κB, IL‑6, IL‑1β, IL‑10, ERα, PR), and RT‑qPCR (TNF‑α, Adipoq). TBT exposure was associated with reduced central IL‑10 alongside increased NF‑κB/IL‑1β/IL‑6 and neurodegenerative changes. Concurrently, ovaries showed NF‑κB/IL‑6 activation, altered TNF‑α/Adipoq expression, follicular degeneration, and disrupted ERα/PR signaling. These dose‑dependent, non‑linear effects occurred simultaneously in both tissues. Fx co‑treatment mitigated many alterations, partially restoring IL‑10, suppressing inflammatory markers, and improving ovarian histopathology. These findings indicate that subchronic low-dose TBT exposure is associated with parallel brain–ovary immune–endocrine-related alterations, supporting the concept that endocrine disruptors can perturb integrated central–peripheral immune–endocrine networks without implying direct endocrine dysfunction.
No takes yet. Share an insight, caveat, or question.
Şahin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: